Global Transplant Diagnostic Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Rising prevalence of chronic and infectious diseases, increasing awareness related to the transplant diagnostic procedures and growing R&D activities are some major factors driving the growth of Global Transplant Diagnostic Market.
Global Transplant Diagnostic Market is valued at USD 3.54 Billion in 2020 and expected to reach USD 5.80 Billion by 2027 with a CAGR of 7.3% over the forecast period.
Transplant diagnostics are the tests led before movement/transplantation of the giver organ to recipient patient. HLA typing is one of most extreme significant applications, for example, organ and blood stem cell transplantation. Transplant diagnostics tests incorporate Human leukocyte antigen (HLA) diagnostic testing, PCR-based assay, serological test and blended lymphocyte culture (MLC) measure among others. Organ transplantation is a process where healthy organ from one person (alive/dead) is removed out and placed into recipient’s body (alive) that needs it for effective functioning of life.
Organs that can be medically transplanted are kidneys, heart, lungs, intestine, liver, thymus and pancreas. Tissues that can be medically transplanted are bones, cornea, heart valves, veins, nerves, skin and tendons. Out of the entire most commonly transplanted organ is Kidney which is preceded by liver and then heart. Sir Peter Medawar is known as father of transplantation who worked on graft rejection and acquired immune tolerance in 1944 showed that skin allograft between two mice are rejected.
On march 9th 1981 the first successful heart lung transplant took place at Stanford university hospital. The surgeon, Bruce Reitz, credited the patients recovery to cyclosporine-A.
The COVID-19 pandemic has shown a decline impact on the organ donation and transplantation in countries that have experienced high rates of infection. During COVID-19 pandemic, government imposed a restriction on transportation to reduce the risk of infection which pauses of elective surgeries in all specialties of medicine including the transplant diagnosis. Due to lockdown conditions and social distancing the transplant diagnostic were delayed or postponed. The imposition of lockdown measures urged the R&D personnel as well as clinical trials of the organizations various ways.
Global transplant diagnostic market is segmented on the basis of technology, product & service, organ type, application, end-user and region & country level. Based upon technology, transplant diagnostic market is classified into molecular assay and non-molecular assay. Based upon product & service, the market is divided into reagents, instruments and software’s. Based on organ type, the transplant diagnostic market is classified into kidney, lungs, pancreas and heart. Based upon application, the market is divided into research and diagnostic. Based on organ end-user, the transplant diagnostic market is classified into hospital, research center, transplant center and commercial provider.
The regions covered in this global transplant diagnostic market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of transplant diagnostic is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Some major key players for global transplant diagnostic market report cover prominent players like
Rising occurrence of chronic and infectious diseases is one of the major factors for driving the growth of global transplant diagnostic market. For instance; as indicated by WHO, in 2020, chronic diseases will represent right around three-quarters of all deaths around the world, and that 71% of deaths because of ischemic heart diseases (IHD), 75% of deaths because of stroke, and 70% of deaths because of diabetes will happen in developing nations. In addition, increasing awareness related to the transplant diagnostic procedures is another major factor supplementing the market growth. For example; according to US department of health and human services, 39,718 transfers were performed in 2019.
Also, as indicated by HRSA, in excess of 113,000 individuals are in the waiting list for organ relocate in 2019. As per Health Resources and Services Administration, starting at 2019, each 10 minute an individual is being added to this waiting list for organ transfers.
Furthermore, growing R&D activities in this field are also fostering the growth of global transplant diagnostic market. For instance; in January 2020; the main American transplant diagnostics organization Eurofins Viracor presented its exclusive dd-cfDNA (contributor determined sans cell DNA) test, named Viracor TRAC. The new advancement is an expansion to the company’s wide-ranging collection of kidney transplant diagnostics.
However, high development cost of organ transplant and inappropriate values of the organ and surgery which may hamper the global transplant diagnostic market growth. In spite of that, development of advance technologies for successful organ transplant can offer more opportunities for the further growth of the global transplant diagnostic market over the forecast period.
North America is expected to dominate the global transplant diagnostic market over the forecast period due to technological advancements, rising volume of organ transplantation procedures performed and presence of key players in this region. For instance; in February 2019, Care Dx dispatched the Allosure for lung transfers. According to Health Resources and Services Administration in 2019, the quantity of individuals requiring organ transplantation in the U.S. was 112,568, while the number of organ donor was pretty much as low as 19,267. Asia Pacific is expected to witness a fastest growth rate in the transplant diagnostic market over the forecast period due to the increasing chronic diseases, large patient population and improving healthcare infrastructure in this region.
• Rest of Europe
• South Korea
• Rest Of APAC
• Rest of South America
• Saudi Arabia
• South Africa
• Rest Of MEA
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 3.54 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 5.80 Billion|
|Tables, Charts & Figures:||175|
|Key Players/Companies||Cylex Inc., Transonic, Stryker, LXN Corporation, Alpha Laboratories, Horiba Medical, Randox Laboratories Ltd, Thermo Fisher Scientific Inc., Otsuka Holdings Co Ltd., Medtronic, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Sanofi, Terumo Corporation, Preservation Solutions Inc., Laboratory Corporation of America Holdings, TransMedics Inc., AbbVie Inc., Zimmer Biomet, NHS Blood and Transplant and others|
|Segments Covered||By Technology, By Product & Service, By Organ Type, By Application, By End-User|
|Regional Analysis||North America, U.S., Canada, , Europe, Germany, France, U.K., Italy, Spain, Sweden, Netherland, Turkey, Switzerland, Belgium, Rest of Europe, Asia-Pacific, South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC, Latin America, Mexico, Colombia, Brazil, Argentina, Peru, Rest of South America, Middle East and Africa, Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA|